Glucagon-like peptide-1 receptor agonists (GLP1-RA) in the treatment of mitochondrial diabetes

Maha Lebbar; José Timsit; Cédric Luyton; Lucien Marchand

doi:10.1007/s00592-021-01729-3

Glucagon-like peptide-1 receptor agonists (GLP1-RA) in the treatment of mitochondrial diabetes

Acta Diabetol. 2021 Sep;58(9):1281-1282. doi: 10.1007/s00592-021-01729-3. Epub 2021 May 5.

Authors

Maha Lebbar¹, José Timsit², Cédric Luyton³, Lucien Marchand⁴

Affiliations

¹ Department of Endocrinology and Diabetes, Hospices Civils de Lyon, Lyon, France.
² Department of Diabetes, Hôpital Cochin, APHP, Université de Paris, PRISIS Reference Center for Rare Diseases, Paris, France.
³ Department of Endocrinology and Diabetes, Centre Hospitalier Saint Joseph Saint Luc, 20 Quai Claude Bernard, 69007, Lyon, France.
⁴ Department of Endocrinology and Diabetes, Centre Hospitalier Saint Joseph Saint Luc, 20 Quai Claude Bernard, 69007, Lyon, France. [email protected].

PMID: 33954848
DOI: 10.1007/s00592-021-01729-3

No abstract available

Keywords: Dulaglutide; GLP1-RA; Glucagon-like peptide-1 receptor agonists; MT-TL1 gene; Maternally inherited diabetes and deafness (MIDD); Mitochondrial diabetes.

MeSH terms

DNA, Mitochondrial
Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptide-1 Receptor*
Humans
Hypoglycemic Agents

Substances

DNA, Mitochondrial
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents